Efficacy of Rucaparib

Rucaparib was studied in a major study of 564 patients with ovarian cancer who had cleared the disease (either partially or completely) after receiving platinum-based cancer drugs. The patient taking rucapanib survived for 11 months with no recurrence or worsening of the disease. By inhibiting the activity of the PARP (polymerase chain reaction promoter) enzyme, rucapanib blocks a pathway in the DNA repair process, causing cancer cells to be unable to repair damage to their DNA. This exposes cancer cells to more DNA damage and ultimately leads to cell death. Overall, rucaparib is a promising drug that may provide an effective treatment option in patients with ovarian cancer associated with certain genetic mutations.